Skip to main content
. 2018 Dec 15;21(1):146–155. doi: 10.1016/j.neo.2018.11.010

Figure 3.

Figure 3

(A) Western blotting for CHFR in CHFR-methylated cell lines (RKO and HCT-116) at 24 and 48 hours after 5-Aza-CdR treatment at 5 μM. (B) Irinotecan sensitivity in RKO and HCT-116 cells after 5-Aza-CdR treatment. Cell growth curves and GI50 values were plotted at 72 hours after 5-Aza-CdR treatment following treatment with increasing concentrations of irinotecan. (C) Western blotting for CHFR in CHFR-unmethylated cell lines (SNU-81 and CaCo-2) after CHFR knockdown with siRNA at 24, 48, and 72 hours. (D) Irinotecan sensitivity in SNU-81 and CaCo-2 cells after CHFR knockdown. Cell growth curves and GI50 values were plotted at 72 hours after CHFR knockdown following treatment with increasing concentrations of irinotecan. All values are based on three independent experiments performed in triplicate.